Navigation Links
Gene Therapy Corrected Rare Bleeding Disorder: Study
Date:12/6/2010

By Amanda Gardner
HealthDay Reporter

SUNDAY, Dec. 5 (HealthDay News) -- Using gene therapy, German researchers report that they managed to "correct" a malfunctioning gene responsible for Wiskott-Aldrich syndrome, a rare but devastating childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children vulnerable to certain cancers and dangerous infections.

However, one of the 10 kids in the study developed acute T-cell leukemia, apparently as a result of the viral vector that was used to insert the healthy gene. The boy is currently on chemotherapy, the study authors noted.

"This is a very good first step, but it's a little scary and we need to move to safer vectors," said Dr. Mary Ellen Conley, director of the Program in Genetic Immunodeficiencies at St. Jude Children's Research Hospital in Memphis, Tenn.

"The study shows proof-of-principle that gene therapy with stem cells in a genetic disorder like this has strong potential," added Paul Sanberg, a stem cell specialist who is director of the University of South Florida Center of Excellence for Aging and Brain Repair in Tampa.

Neither Conley nor Sanberg were involved in the study, which is scheduled to be presented Sunday at the annual meeting of the American Society of Hematology in Orlando, Fla.

According to Conley, children (mostly boys) with Wiskott-Aldrich syndrome (WAS) are born with an inherited genetic defect on the X chromosome that affects the number and size of platelets and makes the children remarkably susceptible to easy bleeding and infections, including different types of cancer.

Bone marrow transplants are the main treatment for the disorder which, if they succeed, basically cure the patient.

"They grow up, go to college and they cause problems," said Conley. "But they're not an easy group of patients to transplant."

Even if a good match is found, transplant recipients can go on to have more problems with infections, such as graft-versus-host disease, in which the body basically rejects the foreign elements.

"One of the long-lasting complications is the kids couldn't do this, they couldn't do that, they see themselves as different," Conley said. "Transplants are getting better but we need better therapy, there's no question."

In this study, the researchers inserted a healthy gene capable of producing WAS protein into hematopoietic stem cells (the "granddaddy" cells that give rise to different blood cells), then transferred these stem cells back into the patient using a viral vector. A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.

In fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.

"This is a first step that says you can correct the disease but I think most people would look at it and say the risk of leukemia is something, and that, let's see if we can avoid that," said Conley, whose team at St. Jude is working on a therapy involving a different type of vector. "It's a good start, but I think we have better things coming down the road."

In other news from the conference, another group of German researchers have determined that people who donate peripheral blood stem cells or bone marrow to help save a life don't face any heightened risk of cancer.

Previously there had been some concern that drugs needed to get the stem cells out of the bone marrow and into the bloodstream where they could be accessed might pose a risk of leukemia.

The study was based on questionnaires returned from more than 12,500 donors, which also showed the donors tended to be in good health and were willing to donate again.

Another study found that the drug rituximab (Rituxan), used to treat rheumatoid arthritis and forms of leukemia and lymphoma, could greatly reduce graft-versus-host disease in stem cell transplant recipients.

More information

The National Marrow Donor Program has more on Wiskott-Aldrich syndrome.

SOURCES: Mary Ellen Conley, M.D., director, program in genetic immunodeficiencies, St. Jude Children's Research Hospital, Memphis, Tenn.; Paul Sanberg, Ph.D., D.Sc., distinguished professor, neurosurgery, and director, University of South Florida Center of Excellence for Aging and Brain Repair, Tampa; Dec. 5, 2010, presentations, American Society of Hematology annual meeting, Orlando, Fla.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Worm Therapy Shows Promise for Ulcerative Colitis
2. Sixth global conference on stem cell therapy to be held Jan. 20-21, 2011, in New York City
3. Breast Cancer Rates Lower With Less Hormone Therapy: Study
4. Drop in breast cancer rates directly tied to reduced hormone therapy
5. Gene therapy prevents memory problems in mice with Alzheimers disease
6. Gene therapy for metastatic melanoma in mice produces complete remission
7. Neuralstem files FDA application for first drug therapy
8. Combination therapy improves survival time for patients with advanced liver cancer
9. Gene Therapy Shows Potential Against Heart Failure
10. Hearing loss common following radiation therapy for head and neck cancer
11. Targeted therapy reactivates guardian of the genome in resistant cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Therapy Corrected Rare Bleeding Disorder: Study 
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare ... San Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop ... habits. The workshops cover a broad range of topics, including coaching skills, the ...
(Date:2/12/2016)... ... , ... The Jones Agency, a family owned insurance company with offices serving ... charity drive with the Tarrant Area Food Bank in the hopes of alleviating hunger ... need, the Tarrant County Food Bank offers hope and security to the one in ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Miami Dental Specialists ... to their Miami dental office. Beginning in January, Miami Dental Specialists will offer ... Dental Specialists are the first office to be chosen by the dental implant manufacturer, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. (AIS) ... PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans and ... such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to ...
(Date:2/12/2016)... ... ... The Central Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter ... teens with and without special needs to gather in a safe and supportive environment. Volunteers ... will take place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
Breaking Medicine Technology: